Research programme: moraxella catarrhalis vaccine - BioPort/GlaxoSmithKline

Drug Profile

Research programme: moraxella catarrhalis vaccine - BioPort/GlaxoSmithKline

Latest Information Update: 18 Jan 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Otitis media

Most Recent Events

  • 17 Jun 2003 No development reported - Preclinical for Otitis media in USA (unspecified route)
  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 21 May 2001 GlaxoSmithKline has licensed the vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top